ClinicalTrials.Veeva

Menu
N

Neurology Associates of Ormond Beach | Ormond Beach, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Eslicarbazepine Acetate
Atogepant
Levodopa
KarXT
Ozanimod
Ofatumumab
Orelabrutinib
IMU-838
Teriflunomide
Polypill

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 34 total trials

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

This is a randomized, double-Blind, placebo-controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis.

Active, not recruiting
Relapsing Remitting Multiple Sclerosis
Other: placebo
Drug: orelabrutinib

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with mod...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: KarXT

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib
Locations recently updated

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have particip...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN0...

Enrolling
Psychosis Associated With Alzheimer's Disease
Drug: KarXT
Locations recently updated

This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosag...

Enrolling
Relapsing Multiple Sclerosis (RMS)
Biological: Ofatumumab approved dose
Biological: Ofatumumab new dose

The goal of this clinical trial is to assess the clinical response to a drug combination type of polypill in patients with AD after 180 days of treat...

Enrolling
Alzheimer Disease
Drug: MAR

Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Re...

Enrolling
Multiple Sclerosis
Drug: IMU-838 tablets
Drug: Placebo matching IMU-838 tablets

Trial sponsors

Novartis logo
Allergan logo
Eisai logo
Karuna Therapeutics logo
Otsuka logo
Sumitomo Pharma logo
Acadia Pharmaceuticals logo
Actelion Pharmaceuticals logo
A
Amgen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems